Rivoglitazone
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 185428-18-6 |
PubChem (CID) | 3055168 |
ChemSpider | 2316729 |
UNII | 3A3N0634Q6 |
ChEMBL | CHEMBL2104753 |
Chemical and physical data | |
Formula | C20H19N3O4S |
Molar mass | 397.448 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]
It is being developed by Daiichi Sankyo.
References
- ↑ Schimke K; Davis ™ (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs. 8 (4): 338–44. PMID 17458185.
- ↑ Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC (2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes Obes Metab. 13 (9): 806–13. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364.
This article is issued from Wikipedia - version of the 6/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.